Approval · Notice of Compliance 15689 · 2014
ACT REPAGLINIDE: Notice of Compliance 15689
Issued June 5, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15689
- Date
- June 5, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Oral antidiabetic agent
- Canadian reference product
- GLUCONORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT REPAGLINIDE | 02321475 | Dormant |
| ACT REPAGLINIDE | 02321483 | Dormant |
| ACT REPAGLINIDE | 02321491 | Dormant |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB